Clene (CLNN) Net Change in Cash : $3.29 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Clene Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Clene's Net Change in Cash for the three months ended in Mar. 2024 was $-7.09 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $3.29 Mil.

Clene Net Change in Cash Historical Data

The historical data trend for Clene's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Net Change in Cash Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

-7.99

50.49

-8.93

-31.96

10.49

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial													0.11	30.80	-7.13	-13.29	-7.09

Clene Net Change in Cash Calculation

Clene's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-30.171	+	-1.499	+	42.163	+	-0.004
	=	10.49

Clene's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -7.082 + 0.071 + -0.019 + -0.059

= -7.09

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clene Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Clene's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (CLNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Net Change in Cash

Comparable Companies

RANI LGVN KRON TPST TIL CTCX SYRS CLSD SLDB CRDF OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Executives

David J Matlin director

Matthew Kiernan director 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901

Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031

Robert Dee Etherington director, officer: Chief Executive Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

John Henry Stevens director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206

Alison Mosca director 26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035

Jonathon Gay director 177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115

General Resonance Llc 10 percent owner 6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121

Robert Glanzman officer: Chief Medical Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

Morgan R Brown officer: Chief Financial Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108

Vallerie Mclaughlin director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

Mark Mortenson officer: Chief Science Officer 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901

Fiona Costello director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

Shalom Jacobovitz director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

Clene (CLNN) Headlines

From GuruFocus

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
By Marketwired • 09-28-2023

Clene to Participate in the Maxim Group Virtual Healthcare Conference
By sperokesalga sperokesalga • 06-15-2023

Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45.1M NINDS Grant Highlighted
By GuruFocus Research • 11-07-2023

Clene's CNM-Au8� Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
By sperokesalga sperokesalga • 06-15-2023

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
By Stock market mentor Stock market mentor • 01-11-2023

Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8� in Non-Active Progressive Multiple Sclerosis
By sperokesalga sperokesalga • 05-25-2023

Clene Announces Launch of Proposed Public Offering
By sperokesalga sperokesalga • 06-15-2023

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8� Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
By Value_Insider Value_Insider • 11-28-2022

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
By Value_Insider Value_Insider • 12-12-2022

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8� Treatment Improved Brain Neuronal Structural Integrity
By sperokesalga sperokesalga • 02-13-2023

David J Matlin	director
Matthew Kiernan	director	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington	director, officer: Chief Executive Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Alison Mosca	director	26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay	director	177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc	10 percent owner	6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman	officer: Chief Medical Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown	officer: Chief Financial Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson	officer: Chief Science Officer	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121